MaxCyte (MXCT) Set to Announce Earnings on Wednesday

MaxCyte (NASDAQ:MXCT - Get Free Report) is scheduled to post its earnings results after the market closes on Wednesday, November 6th. Analysts expect MaxCyte to post earnings of ($0.13) per share for the quarter. MaxCyte has set its FY 2024 guidance at EPS.Parties that are interested in participating in the company's conference call can do so using this link.

MaxCyte (NASDAQ:MXCT - Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.05. The business had revenue of $10.43 million during the quarter, compared to the consensus estimate of $8.20 million. MaxCyte had a negative return on equity of 15.52% and a negative net margin of 77.97%. During the same quarter last year, the company earned ($0.10) earnings per share. On average, analysts expect MaxCyte to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MaxCyte Trading Up 0.3 %

Shares of NASDAQ MXCT traded up $0.01 during midday trading on Wednesday, reaching $3.58. The company had a trading volume of 106,520 shares, compared to its average volume of 506,882. The stock has a market cap of $376.51 million, a P/E ratio of -10.50 and a beta of 1.39. MaxCyte has a 1 year low of $2.92 and a 1 year high of $5.55. The business's 50-day simple moving average is $3.93 and its 200 day simple moving average is $4.19.

Insider Buying and Selling at MaxCyte

In related news, EVP Thomas M. Ross sold 15,476 shares of MaxCyte stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $4.54, for a total transaction of $70,261.04. Following the completion of the sale, the executive vice president now owns 25,000 shares of the company's stock, valued at $113,500. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, EVP Thomas M. Ross sold 15,476 shares of the firm's stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $4.54, for a total transaction of $70,261.04. Following the completion of the transaction, the executive vice president now owns 25,000 shares of the company's stock, valued at $113,500. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Stanley C. Erck sold 21,607 shares of the firm's stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $3.71, for a total transaction of $80,161.97. Following the transaction, the director now directly owns 269,118 shares of the company's stock, valued at approximately $998,427.78. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 72,850 shares of company stock worth $292,898. 3.00% of the stock is currently owned by insiders.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.